Section Arrow
Quote
PHAT.NASDAQ
- Phathom Pharmaceuticals
Quotes are at least 15-min delayed:2025/12/22 06:52 EST
Pre Market
Last
 17.64
+0.11 (+0.63%)
Bid
16
Ask
18.5
High 18.06 
Low 17.63 
Volume 24 
Regular Hours (Closed)
Last
 17.53
+1.25 (+7.68%)
Day High 
17.705 
Prev. Close
16.28 
1-M High
16.61 
Volume 
2.38M 
Bid
16
Ask
18.5
Day Low
16.39 
Open
16.39 
1-M Low
14.12 
Market Cap 
1.16B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.89 
20-SMA 14.89 
50-SMA 14.11 
52-W High 17.705 
52-W Low 2.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.76/-0.72
Enterprise Value
1.36B
Balance Sheet
Book Value Per Share
-5.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
55.25M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.18+3.29+30.21%-- 
Pre Market 14.2 +0.02 +0.14%
RXRXRecursion Pharmaceuticals4.26-0.18-4.05%-- 
Pre Market 4.39 +0.13 +3.05%
IBRXImmunityBio2.08-0.01-0.48%-- 
Pre Market 2.1 +0.02 +0.96%
PBMPsyence Biomedical Ltd1-0.46-31.51%0.04PE
Pre Market 0.9999 -0.0001 -0.01%
GOVXGeoVax Labs0.1592-0.0809-33.69%-- 
Pre Market 0.1682 +0.009 +5.65%
Industry overview quotes are at least 15 minutes delayed
Business Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.